when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog
drugs
Xtandi

drug

enzalutamide

Marketedupdated 3mo ago

by Alessa Therapeutics Inc

Approved

community read0 votes

🐶 often sniffed alongside

top 3

tagApproval112 co-mentions · 28 sources
drugXTANDI112 co-mentions · 28 sources
tagSmall Molecule56 co-mentions · 28 sources

indications

investigational

Prostate Cancer

all catalysts(28)

approval · 28

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

XTANDI (ENZALUTAMIDE) — FDA approval

view all 28 catalysts →

Trials studying enzalutamide

phase2An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)active not recruitingn=165
phase3Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Studyenrolling by invitationn=5,000
phase3A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)recruitingn=1,314
phase1Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancerrecruitingn=479
phase2Pan Tumor Rollover Studyrecruitingn=1,500
phase3A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Studyactive not recruitingn=1,000
phase3The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)recruitingn=520
phase2A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomasrecruitingn=300

more trials →

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 24, 2026

2 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (17)

Feb 23, 2037method-of-use (U-4104)US 12161628
Feb 23, 2037method-of-use (U-4104)US 12161628
Feb 23, 2037method-of-use (U-4101)US 12161628
Sep 11, 2033formulationUS 11839689
Sep 11, 2033formulationUS 11839689
Sep 11, 2033method-of-use (U-4314)US 12447128
Sep 11, 2033method-of-use (U-4365)US 12502357
Sep 11, 2033method-of-use (U-4365)US 12502357
Aug 13, 2027compositionUS 7709517356d
Aug 13, 2027compositionUS 7709517356d
Aug 13, 2027compositionUS 7709517356d
Aug 24, 2026method-of-use (U-3763)US 81832742d
Aug 24, 2026method-of-use (U-3763)US 81832742d
Aug 24, 2026method-of-use (U-3763)US 81832742d
May 15, 2026method-of-use (U-3763)US 9126941
May 15, 2026method-of-use (U-3763)US 9126941
May 15, 2026method-of-use (U-3763)US 9126941

FDA exclusivities (3)

Nov 17, 2026I-926Indication (3y)87d
Nov 17, 2026I-926Indication (3y)87d
Nov 17, 2026I-926Indication (3y)87d

News(3)

Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
biopharma_dive · 15d ago
Alpha-Emitting Therapies in Metastatic Castration-Resistant Prostate Cancer
Dr. Johann De Bono and Dr. Pedro Barata discuss the evolving role of alpha-emitting radiopharmaceutical therapies in metastatic castration-resistant prostate cancer (mCRPC), with a focus on radium…
onclive · 3mo ago
GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.
onclive · 3mo ago

brand

Xtandi

generic

enzalutamide

indication

Prostate Cancer

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 9m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?